Improving the Therapeutic Relevance of Muscle Stem Cells
As reported by the Stem Cell correspondent Stuart P. Atkinson, the research group of McGowan Institute for Regenerative Medicine faculty member Johnny Huard, PhD (pictured top), professor in the Departments of Orthopaedic Surgery, Molecular Genetics, Biochemistry, Bioengineering, and Pathology, the Henry J. Mankin endowed chair in orthopaedic surgery research, and the director of the Stem Cell Research Center, has previously isolated and characterized muscle-derived stem cells (MDSCs) which have been shown by various groups by being able to undergo osteogenic differentiation given the correct stimuli. They are therefore a potential alternative to bone marrow-derived mesenchymal stem cells for bone tissue engineering. One of these stimuli is continued exposure to bone morphogenetic proteins (BMP), hindered by the short half-lives in vivo and the requirement of maintaining a localized concentration. The team, including McGowan Institute for Regenerative Medicine faculty member Yadong Wang, PhD (pictured bottom), the William Kepler Whiteford professor in bioengineering with adjunct positions in chemical engineering and surgery at the University of Pittsburgh, has also devised a delivery strategy; a poly(ethylene argininylaspartate diglyceride)(PEAD)-heparin complex loaded with BMP2 which forms an emulsion-like aggregation of organic molecules separated from the aqueous phase, or a coacervate, previously used to effectively deliver fibroblast growth factor-2 (FGF2) for therapeutic angiogenesis. Now, in a report in Stem Cells Translational Medicine, they report on the use of this system with BMP2 to stimulate osteogenesis in MDSCs in vitro and in vivo.